SCHEMBL580445

SCHEMBL580445

Cc1ccc(O)c(C(CC(N)(C(C)C)C(C)C)c2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
LMNA P02545 4/20 0.56
CHRM1 P11229 3/20 0.56
CHRM2 P08172 2/20 0.56
CHRM5 P08912 2/20 0.56
CHRM3 P20309 2/20 0.56
HRH1 P35367 2/20 0.56
ADRA1A P35348 2/20 0.56
ESR1 P03372 1/20 0.56
CHRM4 P08173 1/20 0.56
KCNE1 P15382 1/20 0.56
PTGS1 P23219 1/20 0.56
HRH2 P25021 1/20 0.56
HTR2A P28223 1/20 0.56
SLC6A4 P31645 1/20 0.56
OPRK1 P41145 1/20 0.56
KCNQ1 P51787 1/20 0.56
KCNH2 Q12809 1/20 0.56
CACNA1C Q13936 1/20 0.56
SCN5A Q14524 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5670305 0.99 MAPT (0.55) MAPTLMNACHRM1CHRM2CHRM5
Cadaverine Tartrate SCHEMBL5269127 0.92 CHRM2 (0.62) MAPTLMNACHRM1CHRM2CHRM5
Bromide SCHEMBL4662476 0.85 MAPT (0.60) MAPTLMNACHRM1CHRM2CHRM5
SCHEMBL1354181 0.84 LMNA (0.40) MAPTLMNACHRM1CHRM2CHRM5
SCHEMBL5683062 0.83 IDO1 (0.40) MAPTLMNACHRM1CHRM2CHRM5
SCHEMBL10514001 0.82 TSHR (0.43) MAPTLMNACHRM1CHRM2CHRM5
SCHEMBL2781332 0.81 KMT2A (0.39) MAPTLMNACHRM1CHRM2CHRM5
SCHEMBL8109866 0.79 ERCC1 (0.39) MAPTLMNACHRM1CHRM2CHRM5
Hydrochloric Acid SCHEMBL8096376 0.79 IGF1R (0.37) MAPTLMNACHRM1CHRM2CHRM5
SCHEMBL8106269 0.79 CA12 (0.43) MAPTLMNACHRM1CHRM2CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3104848-B1 INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT CRYSTEC LTD (GB) 2020-05-06 EP claimed
WO-2018035157-A1 COMPOSITIONS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE AXOVANT SCIENCES GMBH (CH) 2018-02-22 WO claimed
EP-2323967-A2 FESOTERODINE COMPRISING A REDUCED AMOUNT OF DEHYDROXYFESOTERODINE Actavis Group PTC EHF (IS) 2011-05-25 EP claimed
WO-2010010464-A2 FESOTERODINE SUBSTANTIALLY FREE OF DEHYDROXY IMPURITY ACTAVIS GROUP PTC EHF (IS) 2010-01-28 WO claimed
EP-1434574-A2 TOLTERODINE METABOLITES Bridge Pharma, Inc. (US) 2004-07-07 EP claimed
WO-2003002059-A2 TOLTERODINE METABOLITES BRIDGE PHARMA, INC. (US) 2003-01-09 WO claimed
US-11759420-B2 Inhalable particles CRYSTEC LTD (GB) 2023-09-19 US disclosed
CN-115406975-A Tolterodine tartrate raw material and method for detecting ethanol in preparation of tolterodine tartrate raw material 山东新时代药业有限公司 2022-11-29 CN disclosed
US-20220331243-A1 INHALABLE PARTICLES CRYSTEC LTD (GB) 2022-10-20 US disclosed
CN-115112784-A Method for detecting enantiomer in tolterodine tartrate 山东新时代药业有限公司 2022-09-27 CN disclosed
US-11351115-B2 Inhalable particles CRYSTEC LTD (GB) 2022-06-07 US disclosed
US-20200230053-A1 Inhalable Particles CRYSTEC LTD (GB) 2020-07-23 US disclosed
EP-3104848-B1 INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT CRYSTEC LTD (GB) 2020-05-06 EP disclosed
EP-1496882-A1 TOLTERODINE SALTS Pharmacia & Upjohn Company LLC (US) 2005-01-19 EP disclosed
WO-2004105735-A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TOLTERODINE AND PROCESSES FOR THEIR PREPARATION RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 WO disclosed
EP-1461306-A1 QUATERNARY AMMONIUM COMPOUNDS AND THEIR USE AS ANTIMUSCARINIC AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-09-29 EP disclosed
WO-2003090734-A1 TOLTERODINE SALTS PHARMACIA & UPJOHN COMPANY LLC. (US) 2003-11-06 WO disclosed
WO-2003035599-A1 QUARTERNARY AMMONIUM COMPOUNDS AND THEIR USE AS ANTIMUSCARINIC AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-05-01 WO disclosed
EP-1039882-A1 THERAPEUTIC FORMULATION FOR ADMINISTERING TOLTERODINE WITH CONTROLLED RELEASE Pharmacia & Upjohn Aktiebolag (SE) 2000-10-04 EP disclosed
WO-2000012069-A1 THERAPEUTIC FORMULATION FOR ADMINISTERING TOLTERODINE WITH CONTROLLED RELEASE PHARMACIA & UPJOHN AB (SE) 2000-03-09 WO disclosed